TY - JOUR
T1 - Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits
AU - Rodriguez, Ernesto
AU - Boelaars, Kelly
AU - Brown, Kari
AU - Madunić, Katarina
AU - van Ee, Thomas
AU - Dijk, Frederike
AU - Verheij, Joanne
AU - Li, R. J.Eveline
AU - Schetters, Sjoerd T.T.
AU - Meijer, Laura L.
AU - Le Large, Tessa Y.S.
AU - Driehuis, Else
AU - Clevers, Hans
AU - Bruijns, Sven C.M.
AU - O’Toole, Tom
AU - van Vliet, Sandra J.
AU - Bijlsma, Maarten F.
AU - Wuhrer, Manfred
AU - Kazemier, Geert
AU - Giovannetti, Elisa
AU - Garcia-Vallejo, Juan J.
AU - van Kooyk, Yvette
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%. Despite the fact that changes in glycosylation patterns during tumour progression have been reported, no systematic approach has been conducted to evaluate its potential for patient stratification. By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status. These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3. Moreover, these fucosylated glycans can serve as ligands for DC-SIGN positive tumour-associated macrophages, modulating their activation and inducing the production of IL-10. Our results show mechanisms by which the glyco-code contributes to the tolerogenic microenvironment in PDAC.
AB - Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%. Despite the fact that changes in glycosylation patterns during tumour progression have been reported, no systematic approach has been conducted to evaluate its potential for patient stratification. By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status. These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3. Moreover, these fucosylated glycans can serve as ligands for DC-SIGN positive tumour-associated macrophages, modulating their activation and inducing the production of IL-10. Our results show mechanisms by which the glyco-code contributes to the tolerogenic microenvironment in PDAC.
UR - https://www.scopus.com/pages/publications/85122828260
U2 - 10.1038/s42003-021-02934-0
DO - 10.1038/s42003-021-02934-0
M3 - Article
C2 - 35017635
AN - SCOPUS:85122828260
SN - 2399-3642
VL - 5
JO - Communications Biology
JF - Communications Biology
IS - 1
M1 - 41
ER -